Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Pfizer (PFE)

Pfizer completes $6.0 billion offering of seven series of notes due 2027 to 2065

Neutral Impact 3 of 5 financing Written later

Pfizer completed a public offering of seven series of notes with total principal of $6.0 billion, due between 2027 and 2065. The notes were issued under an indenture with The Bank of New York Mellon as trustee, and the underwriting agreement was dated November 18, 2025. The filing reports the terms of the debt but does not state how Pfizer plans to use the proceeds.

Key points

  • Seven series: floating rate notes due 2027 ($500 million), 3.875% notes due 2027 ($1.0 billion), 4.200% notes due 2030 ($1.0 billion), 4.500% notes due 2032 ($1.25 billion), 4.875% notes due 2035 ($1.25 billion), 5.600% notes due 2055 ($500
  • Notes were issued under the Sixth Supplemental Indenture dated November 21, 2025, with The Bank of New York Mellon as trustee
  • Underwriting and pricing agreements dated November 18, 2025, with Citigroup Global Markets, Deutsche Bank Securities, J.P. Morgan Securities and Mizuho Securities USA as representatives

The filing

CompanyPfizer (PFE)
Form8-K, current report
Filed with the SECNov 21, 2025, 4:16 PM ET
Accession number0001193125-25-291406

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 2:16 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 21, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.